Corvus Pharmaceuticals, Inc. CRVS
Corvus Pharmaceuticals, Inc. (Nasdaq: CRVS) is an oncology drug developer. Its lead program, soquelitinib (CPI-818), is in Phase 3 for relapsed/refractory peripheral T cell lymphoma (PTCL). Its next catalyst on record is soquelitinib - atopic dermatitis (Angel Pharmaceuticals China Phase 1b/2): Initial results from cohort 1 (Q1 2027).
Upcoming catalysts
No catalyst is dated to the next 30 days or to an FDA action date.
Next further out: soquelitinib - atopic dermatitis (Angel Pharmaceuticals China Phase 1b/2) — Initial results from cohort 1 (Q1 2027). 7 catalysts on record beyond the next 30 days; subscribers see each with its filing sentence.
Pipeline
| Program | Indication | Modality | Stage |
|---|---|---|---|
| soquelitinib | relapsed/refractory peripheral T cell lymphoma | small molecule | Phase 3 |
| soquelitinib | atopic dermatitis | small molecule | Phase 2 |
| soquelitinib | autoimmune lymphoproliferative syndrome (ALPS) | small molecule | Phase 2 |
| ciforadenant | metastatic renal cell carcinoma (combination with ipilimumab/nivolumab) | small molecule | Phase 2 |
| soquelitinib | hidradenitis suppurativa | small molecule | Phase 1 |
| mupadolimab | cancers and infectious diseases | antibody | Phase 1 |
| soquelitinib | asthma | small molecule | Pre-clinical |
Recent results and decisions
- Nov 5, 2026positive Three ALPS patients completed 360 days of soquelitinib treatment with no grade 3 or 4 adverse events and all showed positive responses.
The treatment was well tolerated, with no grade 3 or 4 adverse events and no interruptions in therapy. All three patients were able to discontinue background medications including steroids and reported improvement in ALPS related systemic symptoms.
Filing
For subscribers
- Cash runway against each catalyst, with the company's own runway statement
- Track record: every Phase 3 readout, FDA decision and guidance slip since 2014
- Expected move for each dated catalyst, from comparable past events
- Phase 2 evidence behind each Phase 3 readout
- Companies on the same target or class
- Full catalyst list with filing sentences, deals, registered trials, Excel export
Other phase 3 oncology companies
- Astrazeneca PLC AZN
- Gilead Sciences, Inc. GILD
- Moderna, Inc. MRNA
- Revolution Medicines, Inc. RVMD
- Genmab A/S GMAB
- BioNTech SE BNTX
- Guardant Health, Inc. GH
- Exelixis, Inc. EXEL
The free Monday brief
Last week's readouts and FDA decisions and the dated catalysts in the week ahead, each with its filing sentence.